Can I read Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry on EtoBox?

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry by Margaret L. Salisbury; Craig S. Conoscenti; Daniel A. Culver; Eric Yow; Megan L. Neely; Shaun Bender; Nadine Hartmann; Scott M. Palmer; Thomas B. Leonard; Albert Baker; Scott Beegle; John Belperio; Rany Condos; Francis Cordova; Daniel A. Culver; Daniel Dilling; John Fitzgerald; Kevin R. Flaherty; Kevin Gibson; Mridu Gulati; Kalpalatha Guntupalli; Nishant Gupta; Amy Hajari Case; David Hotchkin; Tristan Huie; Robert Kaner; Hyun Kim; Lisa Lancaster; Joseph A. Lasky; Doug Lee; Timothy Liesching; Randolph Lipchik; Jason Lobo; Tracy Luckhardt (formerly Joao de Andrade); Yolanda Mageto; Numaan Malik; Prema Menon; Lake Morrison; Andrew Namen; Justin Oldham; Tessy Paul; Anna Podolanczuk; Mary Porteous; Rishi Raj; Murali Ramaswamy; Tonya Russell; Paul Sachs; Zeenat Safdar; Shirin Shafazand; Ather Siddiqi; Barry Sigal; Mary Strek; Sally Suliman; Jeremy Tabak; Rajat Walia; Timothy Whelan is a Medicine article available to read on EtoBox.

What is Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry about?

**Rationale:** Two antifibrotic medications, nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States. Few data have been published on the use of these medications in clinical practice. **Objectives:** To investigate patterns of use of antifibrotic medications in the United States. **Methods:** The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry, a multicenter U.S. registry, has enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the past 6 months. Data from patients enrolled from June 5, 2014, to March 4, 2018, were used to determine antifibrotic medication use (“treatment”) in the enrollment window and in a follow-up window approximately 6 months later. Associations between patient characteristics and treatment status were tested using logistic regression. **Results:** Overall, 551 of 782 eligible patients (70.5%) were treated in the enrollment window. Younger age, lower forced vital capacity percentage predicted, oxygen use with activity, worse self-rated health (based on the Short Form 12 or St. George’s Respiratory Questionnaire score), referral to the en

Who reads Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry?

Author

Margaret L. Salisbury; Craig S. Conoscenti; Daniel A. Culver; Eric Yow; Megan L. Neely; Shaun Bender; Nadine Hartmann; Scott M. Palmer; Thomas B. Leonard; Albert Baker; Scott Beegle; John Belperio; Rany Condos; Francis Cordova; Daniel A. Culver; Daniel Dilling; John Fitzgerald; Kevin R. Flaherty; Kevin Gibson; Mridu Gulati; Kalpalatha Guntupalli; Nishant Gupta; Amy Hajari Case; David Hotchkin; Tristan Huie; Robert Kaner; Hyun Kim; Lisa Lancaster; Joseph A. Lasky; Doug Lee; Timothy Liesching; Randolph Lipchik; Jason Lobo; Tracy Luckhardt (formerly Joao de Andrade); Yolanda Mageto; Numaan Malik; Prema Menon; Lake Morrison; Andrew Namen; Justin Oldham; Tessy Paul; Anna Podolanczuk; Mary Porteous; Rishi Raj; Murali Ramaswamy; Tonya Russell; Paul Sachs; Zeenat Safdar; Shirin Shafazand; Ather Siddiqi; Barry Sigal; Mary Strek; Sally Suliman; Jeremy Tabak; Rajat Walia; Timothy Whelan

Publisher

American Thoracic Society

Published

2020

Language

EN

Field

Medicine (Health Sciences)